Page 2 - ப்ரிஸில ஹார்லன் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from ப்ரிஸில ஹார்லன். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In ப்ரிஸில ஹார்லன் Today - Breaking & Trending Today

Blue Earth Diagnostics: The Lancet Publishes Results of Axumin (Fluciclovine F 18) PET Imaging Study Demonstrating Improved Patient Outcomes in Patients with Recurrent Prostate Cancer


(0)
- Treatment informed by Axumin PET imaging significantly improved event-free-survival for men with recurrent prostate cancer at three and four years -
- Winship Cancer Institute of Emory University s EMPIRE-1 trial is first-of-its-kind randomized patient outcomes study of amino acid PET imaging in influencing a cancer control endpoint -
Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, is pleased to share news of the publication of a study from researchers at Winship Cancer Institute of Emory University (Winship) evaluating Axumin (fluciclovine F 18) PET imaging in men with recurrent prostate cancer. The randomized, prospective study showed that Axumin-guided post-prostatectomy radiation therapy increased biochemical event-free survival rates in men with recurrent disease. Among 165 patients whose prostate cancer had returned following surgical removal of their prostate, 7 ....

United States , United Kingdom , Emory University , Karenm Xu , Eduard Schreibmann , Davidm Schuster , Omer Kucuk , David Gauden , Josephw Shelton , Asheshb Jani , Mehmeta Bilen , Bradley Carthon , Georgina Mowatt , Olayinkaa Abiodun Ojo , Priscilla Harlan , Preteshr Patel , Mark Goodman , Sherrie Cooper , Bruce Hershatter , Kostenloser Wertpapierhandel , Peterj Rossi , Shreyass Joshi , Subir Goyal , Mike Beyer , Raghuveer Halkar , Winship Cancer Institute Of Emory University ,

Monopar and NorthStar Announce Patent Filing on Promising Radiopharmaceutical Discovery


Share:
WILMETTE, Ill. and BELOIT, Wis., May 24, 2021 (GLOBE NEWSWIRE) Monopar Therapeutics Inc. (NASDAQ:MNPR) and NorthStar Medical Radioisotopes, LLC, today announced the filing of a provisional patent with the U.S. Patent and Trademark Office (USPTO) titled Bio-Targeted Radiopharmaceutical Compositions Containing Ac-225 and Methods of Preparation. Radiopharmaceutical therapy is a promising approach to treat cancer and other diseases using radioactive metals bound with proteins/antibodies to target and kill cells. Actinium-225 (Ac-225) is emerging as a radioactive isotope of choice for radiopharmaceuticals due to favorable properties such as its long half-life, high potency, and induction of localized cell death. ....

United States , Paul Estrem , Alisa Holst , James Harvey , Kimr Tsuchimoto , Priscilla Harlan , Andrew Mazar , Exchange Commission , Trademark Office , Monopar Therapeutics Inc , Northstar Medical Radioisotopes , Chief Scientific Officer , Star Medical Radioisotopes , Drug Administration , Private Securities Litigation Reform Act , Vice President , Chief Financial , President Sales , ஒன்றுபட்டது மாநிலங்களில் , லிசா ஹோல்ஸ்ட் , ஜேம்ஸ் ஹார்வி , ப்ரிஸில ஹார்லன் , ஆண்ட்ரூ மசார் , பரிமாற்றம் தரகு , முத்திரை அலுவலகம் , தலைமை அறிவியல் அதிகாரி ,